Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander

Kazuaki Taguchi, Yukino Urata, Makoto Anraku, Hiroshi Watanabe, Keiichi Kawai, Teruyuki Komatsu, Eishun Tsuchida, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human serum albumin (HSA) is used clinically as a plasma expander in patients with hypoalbuminemia and can also function as a drug carrier. However, the administered HSA is readily eliminated from the blood circulation under pathological conditions, especially the nephrotic syndrome. In this study, we present data on the pharmacokinetics of a structurally defined HSA dimer [two HSA molecules that are cross-linked by reaction with 1,6-bis(maleimido)hexane via Cys34] in nephrotic rats and its superior circulation persistence, owing to the molecular size effect. The half-time (t1/2) of the HSA dimer persisted in the circulation 1.3 times longer than that of monomeric HSA in normal rats, primarily because of the suppression of the accumulation of the HSA dimer in the skin and muscle. In nephrotic rats, the t1/2 of the HSA monomer decreased considerably, whereas the HSA dimer remained unaltered in the blood stream, similar to that for normal rats. As a result, the t1/2 of the HSA dimer was 2-fold longer than that of the HSA monomer. This longer t1/2 can be attributed to the fact that accumulation in the kidney and urinary excretion of the HSA dimer were significantly suppressed. The cross-linked HSA dimer shows a longer blood circulation than native HSA monomer in nephrotic rats, which can be attributed to the suppression of renal filtration and leakage into the extravascular space. This HSA dimer has the potential for use as a drug carrier, new plasma expander, and an artificial albumin-based oxygen carrier under a high glomerular permeability condition such as nephrosis.

Original languageEnglish
Pages (from-to)2124-2129
Number of pages6
JournalDrug Metabolism and Disposition
Volume38
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1
Externally publishedYes

Fingerprint

Serum Albumin
Drug Carriers
Blood Circulation
Nephrosis
Kidney
Hypoalbuminemia
Cross Reactions
Nephrotic Syndrome
Hexanes
Albumins
Permeability
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander. / Taguchi, Kazuaki; Urata, Yukino; Anraku, Makoto; Watanabe, Hiroshi; Kawai, Keiichi; Komatsu, Teruyuki; Tsuchida, Eishun; Maruyama, Toru; Otagiri, Masaki.

In: Drug Metabolism and Disposition, Vol. 38, No. 12, 01.12.2010, p. 2124-2129.

Research output: Contribution to journalArticle

Taguchi, K, Urata, Y, Anraku, M, Watanabe, H, Kawai, K, Komatsu, T, Tsuchida, E, Maruyama, T & Otagiri, M 2010, 'Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander', Drug Metabolism and Disposition, vol. 38, no. 12, pp. 2124-2129. https://doi.org/10.1124/dmd.109.031989
Taguchi, Kazuaki ; Urata, Yukino ; Anraku, Makoto ; Watanabe, Hiroshi ; Kawai, Keiichi ; Komatsu, Teruyuki ; Tsuchida, Eishun ; Maruyama, Toru ; Otagiri, Masaki. / Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander. In: Drug Metabolism and Disposition. 2010 ; Vol. 38, No. 12. pp. 2124-2129.
@article{b912e5f6819b45018c6d0ef6581fcce9,
title = "Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander",
abstract = "Human serum albumin (HSA) is used clinically as a plasma expander in patients with hypoalbuminemia and can also function as a drug carrier. However, the administered HSA is readily eliminated from the blood circulation under pathological conditions, especially the nephrotic syndrome. In this study, we present data on the pharmacokinetics of a structurally defined HSA dimer [two HSA molecules that are cross-linked by reaction with 1,6-bis(maleimido)hexane via Cys34] in nephrotic rats and its superior circulation persistence, owing to the molecular size effect. The half-time (t1/2) of the HSA dimer persisted in the circulation 1.3 times longer than that of monomeric HSA in normal rats, primarily because of the suppression of the accumulation of the HSA dimer in the skin and muscle. In nephrotic rats, the t1/2 of the HSA monomer decreased considerably, whereas the HSA dimer remained unaltered in the blood stream, similar to that for normal rats. As a result, the t1/2 of the HSA dimer was 2-fold longer than that of the HSA monomer. This longer t1/2 can be attributed to the fact that accumulation in the kidney and urinary excretion of the HSA dimer were significantly suppressed. The cross-linked HSA dimer shows a longer blood circulation than native HSA monomer in nephrotic rats, which can be attributed to the suppression of renal filtration and leakage into the extravascular space. This HSA dimer has the potential for use as a drug carrier, new plasma expander, and an artificial albumin-based oxygen carrier under a high glomerular permeability condition such as nephrosis.",
author = "Kazuaki Taguchi and Yukino Urata and Makoto Anraku and Hiroshi Watanabe and Keiichi Kawai and Teruyuki Komatsu and Eishun Tsuchida and Toru Maruyama and Masaki Otagiri",
year = "2010",
month = "12",
day = "1",
doi = "10.1124/dmd.109.031989",
language = "English",
volume = "38",
pages = "2124--2129",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "12",

}

TY - JOUR

T1 - Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander

AU - Taguchi, Kazuaki

AU - Urata, Yukino

AU - Anraku, Makoto

AU - Watanabe, Hiroshi

AU - Kawai, Keiichi

AU - Komatsu, Teruyuki

AU - Tsuchida, Eishun

AU - Maruyama, Toru

AU - Otagiri, Masaki

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Human serum albumin (HSA) is used clinically as a plasma expander in patients with hypoalbuminemia and can also function as a drug carrier. However, the administered HSA is readily eliminated from the blood circulation under pathological conditions, especially the nephrotic syndrome. In this study, we present data on the pharmacokinetics of a structurally defined HSA dimer [two HSA molecules that are cross-linked by reaction with 1,6-bis(maleimido)hexane via Cys34] in nephrotic rats and its superior circulation persistence, owing to the molecular size effect. The half-time (t1/2) of the HSA dimer persisted in the circulation 1.3 times longer than that of monomeric HSA in normal rats, primarily because of the suppression of the accumulation of the HSA dimer in the skin and muscle. In nephrotic rats, the t1/2 of the HSA monomer decreased considerably, whereas the HSA dimer remained unaltered in the blood stream, similar to that for normal rats. As a result, the t1/2 of the HSA dimer was 2-fold longer than that of the HSA monomer. This longer t1/2 can be attributed to the fact that accumulation in the kidney and urinary excretion of the HSA dimer were significantly suppressed. The cross-linked HSA dimer shows a longer blood circulation than native HSA monomer in nephrotic rats, which can be attributed to the suppression of renal filtration and leakage into the extravascular space. This HSA dimer has the potential for use as a drug carrier, new plasma expander, and an artificial albumin-based oxygen carrier under a high glomerular permeability condition such as nephrosis.

AB - Human serum albumin (HSA) is used clinically as a plasma expander in patients with hypoalbuminemia and can also function as a drug carrier. However, the administered HSA is readily eliminated from the blood circulation under pathological conditions, especially the nephrotic syndrome. In this study, we present data on the pharmacokinetics of a structurally defined HSA dimer [two HSA molecules that are cross-linked by reaction with 1,6-bis(maleimido)hexane via Cys34] in nephrotic rats and its superior circulation persistence, owing to the molecular size effect. The half-time (t1/2) of the HSA dimer persisted in the circulation 1.3 times longer than that of monomeric HSA in normal rats, primarily because of the suppression of the accumulation of the HSA dimer in the skin and muscle. In nephrotic rats, the t1/2 of the HSA monomer decreased considerably, whereas the HSA dimer remained unaltered in the blood stream, similar to that for normal rats. As a result, the t1/2 of the HSA dimer was 2-fold longer than that of the HSA monomer. This longer t1/2 can be attributed to the fact that accumulation in the kidney and urinary excretion of the HSA dimer were significantly suppressed. The cross-linked HSA dimer shows a longer blood circulation than native HSA monomer in nephrotic rats, which can be attributed to the suppression of renal filtration and leakage into the extravascular space. This HSA dimer has the potential for use as a drug carrier, new plasma expander, and an artificial albumin-based oxygen carrier under a high glomerular permeability condition such as nephrosis.

UR - http://www.scopus.com/inward/record.url?scp=78649531920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649531920&partnerID=8YFLogxK

U2 - 10.1124/dmd.109.031989

DO - 10.1124/dmd.109.031989

M3 - Article

C2 - 20855459

AN - SCOPUS:78649531920

VL - 38

SP - 2124

EP - 2129

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 12

ER -